|
Health-related quality of life (HRQoL) of pembrolizumab (pembro) versus physician choice single-agent paclitaxel, docetaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma (ACC) or squamous cell carcinoma (SCC) of the esophagus that has progressed after first-line standard therapy (KEYNOTE-181). |
|
|
Honoraria - Bristol-Myers Squibb; SERVIER |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Sanofi; SERVIER |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Novartis; Sanofi |
Research Funding - Bayer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Merck; Merck Serono; Sanofi |
|
|
|
Stock and Other Ownership Interests - Merck |
|
Gustavo Colagiovanni Girotto |
Honoraria - Amgen; Bristol-Myers Squibb; Merck Sharp & Dome; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - AstraZeneca; BMS Brazil; Lilly; Merck Serono; Merck Sharp & Dome |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dome; Roche |
|
Christelle De La Fouchardiere |
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; Roche; SERVIER; Shire |
|
Travel, Accommodations, Expenses - Amgen; Amgen; Bristol-Myers Squibb; Celgene; Roche; SERVIER |
|
|
No Relationships to Disclose |
|
Hanneke W.M. Van Laarhoven |
Honoraria - Lilly/ImClone |
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly/ImClone; Nordic Group |
Research Funding - Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen-Cilag (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Nordic Group (Inst); Philips Healthcare (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
Stock and Other Ownership Interests - Novartis; Roche |
Research Funding - Merck Serono |
Travel, Accommodations, Expenses - Celgene |
|
|
|
|
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer Health; Lilly |
Consulting or Advisory Role - Erytech Pharma; Sanofi |
Research Funding - Bristol-Myers Squibb; Merck |